Saturday, February 27

6:00 p.m.-7:35 p.m.   Session 1
Telomere Protection I
Chairperson: Virginia A. Zakian, Princeton University, Princeton, NJ

6:00  Persistent telomere damage induces bypass of mitosis and tetraploidy
       Titia de Lange, Rockefeller University, New York, NY

6:25  The roles of Ku and DNA LIGIV at human telomeres
       Eric Hendrickson, University of Minnesota, Minneapolis, MN

6:50  Dyskeratosis congenita-associated TINF2 mutations affect TRF1 levels and sister telomere cohesion*
       Ghadir Sasa, Baylor College of Medicine, Houston, TX

7:05  TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression*
       Hiroyuki Seimiya, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

7:20  Role of mammalian RAP1 in telomere maintenance, subtelomeric gene silencing, and general transcriptional regulation*
       Paula Martinez, Spanish National Cancer Centre (CNIO), Madrid, Spain

7:35 p.m.-9:00 p.m.   Networking Reception
Sunday, February 28

8:00 a.m.- 9:00 a.m.  Continental Breakfast

9:00 a.m.-9:45 a.m.  Keynote Presentation
*Chairperson: Titia de Lange, Rockefeller University, New York, NY*

9:00  Targeting telomerase for cancer therapeutics
Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX

9:45 a.m.-10:00 a.m.  Break

10:00 a.m.-11:45 a.m.  Session 2
DNA Damage Response and Cancer I
*Chairperson: Roger R. Reddel, Children’s Medical Research Institute, Westmead, NSW, Australia*

10:00  Understanding Fanconi anemia
Simon Boulton, Cancer Research UK, South Mimms, United Kingdom

10:25  TRF2 controls a cell-extrinsic anticancer barrier via activation of natural killer cells
Eric Gilson, ENS de Lyon, Lyon, France

10:50  DNA end processing mediated by Mre11/Rad50 complexes
Tanya Paull, University of Texas, Austin, TX

11:15  A mutation in MRE11 that influences telomere recombination pathways and promotes an efficient bypass of telomere senescence*
Arthur J. Lustig, Tulane University, New Orleans, LA

11:30  Greater variability in telomeres in cancer cells and shorter telomeres in cancer-associated stromal cells are associated with a higher risk of prostate cancer death in surgically treated men*
Alan K. Meeker, Johns Hopkins University School of Medicine, Baltimore, MD

11:45 a.m. -1:45 p.m.  Lunch on Own
1:45 p.m.-3:20 p.m.  
**Session 3**  
**Telomerase I**  
*Chairperson: Titia de Lange, Rockefeller University, New York, NY*

1:45  
**Telomerase action at human telomeres**  
Woodring E. Wright, UT Southwestern Medical Center, Dallas, TX

2:10  
**Regulation of telomerase by shelterin and TERRA**  
Joachim Lingner, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

2:35  
**An RNAi screen for Tert transcriptional regulators identifies HIF1α as critical for telomerase function in murine embryonic stem cells**  
Richard Allsopp, University of Hawaii, Honolulu, HI

2:50  
**HPV E6 protein interacts physically and functionally with the cellular telomerase complex**  
Xuefeng Liu, Georgetown University, Washington, DC

3:05  
**Alternative spliced variants of TERT have extratelomeric function**  
Radmila Hrdlickova, University of Texas, Austin, TX

3:20 p.m.-3:35 p.m.  
**Break**

3:35 p.m.-5:25 p.m.  
**Session 4**  
**Telomerase II**  
*Chairperson: Woodring E. Wright, UT Southwestern Medical Center, Dallas, TX*

3:35  
**Recognizing short S. cerevisiae telomeres for elongation**  
Virginia A. Zakian, Princeton University, Princeton, NJ

4:00  
**Telomerase, stem cells, and Wnt signaling**  
Steven E. Artandi, Stanford University School of Medicine, Stanford, CA

4:25  
**A role for sumo modification in telomere localization and length maintenance**  
Helder Ferreira, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

4:40  
**RTEL is required for genome stability and telomere maintenance**  
Evert-Jan Uringa, Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC, Canada
RecQ helicases interact with shelterin proteins and take part in maintenance and repair of telomeric DNA*  
Avik Ghosh, National Institute on Aging, Baltimore, MD

The interaction of β-catenin and telomerase and its role during carcinogenesis*  
Falk Mancke, Institute of Molecular Medicine and Cell Research, Freiburg, Germany

Dinner on Own

Poster Session A

Monday, March 1

Continental Breakfast

Session 5
DNA Damage Response and Cancer II  
Chairperson: Lorraine S. Symington, Columbia University Medical Center, New York, NY

Double-strand break repair and genomic integrity  
Maria Jasin, Memorial Sloan-Kettering Cancer Center, New York, NY

Mechanisms underlying translocations in B lineage cells  
Frederick W. Alt, Children’s Hospital Boston, Boston, MA

Genetic analysis of chromosome break metabolism in eukaryotic cells  
John H. J. Petrini, Memorial Sloan-Kettering Cancer Center, New York, NY

The role of DNA repair in the sensitivity of telomeric regions to double-strand breaks in human cells*  
John P. Murnane, University of California, San Francisco, CA

Self-complementary mutant telomeric repeats engage an alternative fusion pathway in human cancer cells*  
Bradley A. Stohr, University of California, San Francisco, CA
10:15 a.m.-10:30 a.m.  Break

10:30 a.m.-12:05 p.m.  Session 6  
Telomere Protection II  
Chairperson: María A. Blasco, Spanish National Cancer Center, Madrid, Spain

10:30  Telomere metabolism during the cell cycle revealed by analyzing single telomeres in human cells  
Fuyuki Ishikawa, Kyoto University, Kyoto, Japan

10:55  Evolution of telomere protein complexes involved in telomere replication and new telomere synthesis  
Carolyn Price, University of Cincinnati, Cincinnati, OH

11:20  FEN1 facilitates replication fork re-initiation and ensures telomere stability*  
Sheila A. Stewart, Washington University, St. Louis, MO

11:35  Evidence for chromosome end protection by two distinct telomere architectures*  
Anita Kazda, Gregor Mendel Institute of Molecular Plant Biology, Vienna, Austria

11:50  Telomere lengths, pulmonary fibrosis, and telomerase (tert) mutations*  
Christine Kim Garcia, UT Southwestern Medical Center, Dallas, TX

12:05 p.m.-2:05 p.m.  Lunch on Own

2:05 p.m.-3:50 p.m.  Session 7  
Stem Cells, Cancer, and Telomeres  
Chairperson: Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX

2:05  Reprogramming of chromosome ends: A key step in the generation of iPS cells  
María A. Blasco, Spanish National Cancer Center, Madrid, Spain

2:30  Heritable mutations in telomerase genes and cancer  
Peter M. Lansdorp, University of British Columbia, Vancouver, BC, Canada
2:55 Vaccination strategies against telomerase in cancer
Gary W. Middleton, St. Luke’s Cancer Centre, Guildford, United Kingdom

3:20 In vivo and in vitro inhibition of multiple types of cancer stem cells by the novel telomerase inhibitor imetelstat*
Robert J. Tressler, Geron Inc., Menlo Park, CA

3:35 Telomerase inhibitor imetelstat sensitive and resistant response phenotypes in non-small cell lung cancer*
Robin E. Frink, UT Southwestern Medical Center, Dallas, TX

3:50 p.m.-4:05 p.m. Break

4:05 p.m.-5:40 p.m. Session 8
Telomere Length Regulation
Chairperson: Joachim Lingner, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

4:05 Regulation of telomere replication and end protection in budding yeast
Vicki Lundblad, Salk Institute Cancer Center, La Jolla, CA

4:30 Telomere-driven epigenetic changes during aging
Jan Karlseder, Salk Institute for Biological Studies, La Jolla, CA

4:55 The Est3 protein of Saccharomyces cerevisiae stimulates telomerase catalytic activity through direct interaction with Est2p*
Katherine L. Friedman, Vanderbilt University, Nashville, TN

5:10 Enzymatic requirements of human telomerase for telomere homeostasis and cellular immortalization*
Yasmin D’Souza, McGill University, Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada

5:25 3’end processing of telomerase RNA in fission yeast*
Wen Tang, Stowers Institute for Medical Research, Kansas City, MO

5:40 p.m.-8:00 p.m. Dinner on Own

8:00 p.m.-10:30 p.m. Poster Session B
Tuesday, March 2

7:30 a.m.-8:30 a.m.  Continental Breakfast

8:30 a.m.-10:05 a.m.  Session 9  
Telomere Protection III  
Chairperson: Vicki Lundblad, Salk Institute Cancer Center, La Jolla, CA

8:30  DNA-templated telomere synthesis in cancer and normal cells  
Roger R. Reddel, Children’s Medical Research Institute, Westmead, NSW, Australia

8:55  Telomere dysfunction and fusion in chronic lymphocytic leukemia: Evidence for telomere crisis  
Duncan Baird, Cardiff University, Cardiff, United Kingdom

9:20  Embryonic stem cells and ALT cancer cells share key chromatin players and a common pathway in the regulation of telomere chromatin integrity*  
Lee H. Wong, Murdoch Childrens Research Institute, Parkville, VIC, Australia

9:35  Interaction of MUS81 and BLM is required for telomere recombination*  
Qin Yang, Washington University, St. Louis, MO

9:50  ALT-immortalized human cells are critically dependent on the Fanconi anemia protein FANCD2 to limit BLM-dependent recombination and amplification of telomeric repeat DNA*  
M. Stephen Meyn, Hospital for Sick Children, Toronto, ON, Canada

10:05 a.m.-10:20 a.m.  Break
10:20 a.m.-12:05 p.m.  Session 10
Genome Instability
Chairperson: Maria Jasin, Memorial Sloan-Kettering Cancer Center, New York, NY

10:20  Mechanism and regulation of DNA end resection
Lorraine S. Symington, Columbia University Medical Center, New York, NY

10:45  Cellular senescence and telomeric DNA damage
Fabrizio d’Adda di Fagagna, F.I.R.C. Institute for Molecular Oncology, Milan, Italy

11:10  Interplay between homologous recombination and end joining in maintaining genome stability
Andre Nussenzweig, National Cancer Institute, Bethesda, MD

11:35  Telomere dysfunction induced senescence limits human cancer progression*
Utz Herbig, New Jersey Medical School-UMDNJ, Newark, NJ

11:50  Upregulation of mammalian Sirt1 does not increase longevity but improves health and protects from cancer*
Manuel Serrano, Spanish National Cancer Research Centre, Madrid, Spain

Departure

*Indicates proffered presentation from selected abstracts